GAS5 and hepatocellular carcinoma: Concerning GAS5, several studies have reported that its expression is typically reduced in different cancer types, including hepatocellular carcinoma (HCC) [26,27], head and neck squamous cell carcinoma, glioblastoma, bladder, and non-small cell lung cancer (NSCLC) [28].